Organization (Academic)
Isfahan University of Medical Sciences
ClinicalTrials.gov lists Isfahan University of Medical Sciences as lead sponsor of 149 trials. It has 19 active development programs and 50 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Isfahan University of Medical Sciences: 149 lead-sponsored trials and 1 legal-entity registration.
Disease areas (143)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 9 |
| Diabetes Mellitus | 8 |
| Multiple Sclerosis | 8 |
| Dyslipidemias | 6 |
| Anxiety Disorders | 4 |
Showing 5 of 143 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 1 |
| 2022 | 7 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 10 |
| 2017 | 8 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (19)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| MORPHINE | Multiple Trauma | Phase 3 | 1 |
| Ibuprofen 800 mg | Multiple Trauma | Phase 3 | 1 |
| Ibuprofen 400 mg plus Acetaminophen 1000 mg | Multiple Trauma | Phase 3 | 1 |
| bevacizumab with oral curcumin | Diabetes Mellitus | Phase 2/3 | 1 |
| bevacizumab with oral curcumin | Diabetic Retinopathy | Phase 2/3 | 1 |
Showing 5 of 19 active programs.
Approved assets (50)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| FENTANYL | 3 |
| +/- Bupivacaine HCl | 2 |
| Empagliflozin 25 MG | 1 |
| Fluid therapy | 1 |
| Spinal Anesthesia | 1 |
Showing 5 of 50 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 86% hit target (n=7) | 57% on time (n=7) |
Journals published in (103)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 4 |
| BMC musculoskeletal disorders | 3 |
| Journal of neurology | 3 |
| PloS one | 3 |
| The Cochrane database of systematic reviews | 3 |
Showing 5 of 103 journals.
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Kermanshah University of Medical Sciences | Co sponsors trial with | 1 |
| Semnan University of Medical Sciences | Co sponsors trial with | 1 |
| Madaus Inc | Co sponsors trial with | 1 |
Latest dated events (154)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 154 events.
Biomarker capability evidence (39)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ADM | Trial sponsor | Named in trial inclusion criteria |
| ANK2 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| BARD1 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| BCKDK | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| CRP | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 39 evidence rows.
Biomarkers this organization publishes on (250)
Shown in this order: most publications first.
Showing 5 of 250 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.